Literature DB >> 24823760

Long-term trends in glaucoma-related blindness in Olmsted County, Minnesota.

Mehrdad Malihi1, Edney R Moura Filho1, David O Hodge2, Arthur J Sit3.   

Abstract

OBJECTIVE: To determine the longitudinal trends in the probability of blindness due to open-angle glaucoma (OAG) in Olmsted County, Minnesota, from 1965 to 2009.
DESIGN: Retrospective, population-based cohort study. PARTICIPANTS: All residents of Olmsted County, Minnesota (aged ≥ 40 years) who were diagnosed with OAG between January 1, 1965, and December 31, 2000.
METHODS: All available medical records of every incident case of OAG were reviewed until December 31, 2009, to identify progression to blindness, defined as visual acuity ≤ 20/200 or visual field constriction to ≤ 20°. Kaplan-Meier analysis was used to estimate the cumulative probability of glaucoma-related blindness. Population incidence of blindness within 10 years of diagnosis was calculated using US Census data. Rates for subjects diagnosed in the period 1965-1980 were compared with rates for subjects diagnosed in the period 1981-2000 using log-rank tests and Poisson regression models. MAIN OUTCOME MEASURES: Cumulative probability of OAG-related blindness and population incidence of blindness within 10 years of diagnosis.
RESULTS: Probability of glaucoma-related blindness in at least 1 eye at 20 years decreased from 25.8% (95% confidence interval [CI], 18.5-32.5) for subjects diagnosed in 1965-1980 to 13.5% (95% CI, 8.8-17.9) for subjects diagnosed in 1981-2000 (P = 0.01). The population incidence of blindness within 10 years of the diagnosis decreased from 8.7 per 100,000 (95% CI, 5.9-11.5) for subjects diagnosed in 1965-1980 to 5.5 per 100,000 (95% CI, 3.9-7.2) for subjects diagnosed in 1981-2000 (P = 0.02). Higher age at diagnosis was associated with increased risk of progression to blindness (P < 0.001).
CONCLUSIONS: The 20-year probability and the population incidence of blindness due to OAG in at least 1 eye have decreased over a 45-year period from 1965 to 2009. However, a significant proportion of patients still progress to blindness despite recent diagnostic and therapeutic advancements.
Copyright © 2014 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24823760      PMCID: PMC4038428          DOI: 10.1016/j.ophtha.2013.09.003

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  35 in total

Review 1.  Rochester Epidemiology Project: a unique resource for research in the rheumatic diseases.

Authors:  Hilal Maradit Kremers; Cynthia S Crowson; Sherine E Gabriel
Journal:  Rheum Dis Clin North Am       Date:  2004-11       Impact factor: 2.670

2.  Population and high-risk group screening for glaucoma: the Los Angeles Latino Eye Study.

Authors:  Brian A Francis; Rohit Varma; Cheryl Vigen; Mei-Ying Lai; Jonathan Winarko; Betsy Nguyen; Stanley Azen
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-08-05       Impact factor: 4.799

3.  Models of open-angle glaucoma prevalence and incidence in the United States.

Authors:  H A Quigley; S Vitale
Journal:  Invest Ophthalmol Vis Sci       Date:  1997-01       Impact factor: 4.799

4.  A clinical comparison of visual field testing with a new automated perimeter, the Humphrey Field Analyzer, and the Goldmann perimeter.

Authors:  R W Beck; T J Bergstrom; P R Lichter
Journal:  Ophthalmology       Date:  1985-01       Impact factor: 12.079

5.  Automated perimetry detects visual field loss before manual Goldmann perimetry.

Authors:  J Katz; J M Tielsch; H A Quigley; A Sommer
Journal:  Ophthalmology       Date:  1995-01       Impact factor: 12.079

6.  Rate of visual field loss in progressive glaucoma.

Authors:  M T Rasker; A van den Enden; D Bakker; P F Hoyng
Journal:  Arch Ophthalmol       Date:  2000-04

7.  The number of people with glaucoma worldwide in 2010 and 2020.

Authors:  H A Quigley; A T Broman
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

8.  Estimating the rate of progressive visual field damage in those with open-angle glaucoma, from cross-sectional data.

Authors:  Aimee Teo Broman; Harry A Quigley; Sheila K West; Joanne Katz; Beatriz Munoz; Karen Bandeen-Roche; James M Tielsch; David S Friedman; Jonathan Crowston; Hugh R Taylor; Rohit Varma; M Cristina Leske; Boel Bengtsson; Anders Heijl; Mingguang He; Paul J Foster
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-01       Impact factor: 4.799

9.  Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.

Authors:  Anders Heijl; M Cristina Leske; Bo Bengtsson; Leslie Hyman; Boel Bengtsson; Mohamed Hussein
Journal:  Arch Ophthalmol       Date:  2002-10

10.  The probability of blindness from open-angle glaucoma.

Authors:  M G Hattenhauer; D H Johnson; H H Ing; D C Herman; D O Hodge; B P Yawn; L C Butterfield; D T Gray
Journal:  Ophthalmology       Date:  1998-11       Impact factor: 12.079

View more
  31 in total

1.  Cost-Utility Analysis of Glaucoma Medication Adherence.

Authors:  Paula Anne Newman-Casey; Mariam Salman; Paul P Lee; Justin D Gatwood
Journal:  Ophthalmology       Date:  2019-10-10       Impact factor: 12.079

2.  Why Do People (Still) Go Blind from Glaucoma?

Authors:  Remo Susanna; Carlos Gustavo De Moraes; George A Cioffi; Robert Ritch
Journal:  Transl Vis Sci Technol       Date:  2015-03-09       Impact factor: 3.283

Review 3.  Protecting retinal ganglion cells.

Authors:  T Z Khatib; K R Martin
Journal:  Eye (Lond)       Date:  2017-01-13       Impact factor: 3.775

Review 4.  Precision medicine to prevent glaucoma-related blindness.

Authors:  Sayoko E Moroi; David M Reed; David S Sanders; Ahmed Almazroa; Lawrence Kagemann; Neil Shah; Nakul Shekhawat; Julia E Richards
Journal:  Curr Opin Ophthalmol       Date:  2019-05       Impact factor: 3.761

5.  The Risk of Primary Open-Angle Glaucoma Following Vitreoretinal Surgery-A Population-based Study.

Authors:  Sasha A Mansukhani; Andrew J Barkmeier; Sophie J Bakri; Raymond Iezzi; Jose S Pulido; Cheryl L Khanna; Jeffrey R Bennett; David O Hodge; Arthur J Sit
Journal:  Am J Ophthalmol       Date:  2018-06-27       Impact factor: 5.258

6.  Establishing a Regional Glaucoma Physician Collaborative to Improve Quality of Care.

Authors:  Joshua R Ehrlich; Jeffrey N Wentzloff; Nauman R Imami; Taylor S Blachley; Joshua D Stein; Paul P Lee; Jennifer S Weizer
Journal:  Am J Ophthalmol       Date:  2017-05-05       Impact factor: 5.258

7.  Accuracy of Patient-reported Adherence to Glaucoma Medications on a Visual Analog Scale Compared With Electronic Monitors.

Authors:  Robyn Sayner; Delesha M Carpenter; Susan J Blalock; Alan L Robin; Kelly W Muir; Mary Elizabeth Hartnett; Annette L Giangiacomo; Gail Tudor; Betsy Sleath
Journal:  Clin Ther       Date:  2015-07-09       Impact factor: 3.393

8.  In Vivo Noninvasive Measurement of Young's Modulus of Elasticity in Human Eyes: A Feasibility Study.

Authors:  Arthur J Sit; Shuai-Chun Lin; Arash Kazemi; Jay W McLaren; Christopher M Pruet; Xiaoming Zhang
Journal:  J Glaucoma       Date:  2017-11       Impact factor: 2.503

Review 9.  Macular imaging with optical coherence tomography in glaucoma.

Authors:  Vahid Mohammadzadeh; Nima Fatehi; Adeleh Yarmohammadi; Ji Woong Lee; Farideh Sharifipour; Ramin Daneshvar; Joseph Caprioli; Kouros Nouri-Mahdavi
Journal:  Surv Ophthalmol       Date:  2020-03-19       Impact factor: 6.048

10.  Blindness following bleb-related infection in open angle glaucoma.

Authors:  Hiroki Yamada; Akira Sawada; Yasuaki Kuwayama; Tetsuya Yamamoto
Journal:  Jpn J Ophthalmol       Date:  2014-09-25       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.